<DOC>
	<DOCNO>NCT01189448</DOCNO>
	<brief_summary>Background : When mother contract toxoplasmosis pregnancy , parasite may transmit unborn child . This result congenital toxoplasmosis , may cause damage eye nervous system child . To date , method prove effective prevent transmission . In France , spiramycin usually prescribe woman toxoplasma seroconversion pregnancy , however efficacy determine . The standard treatment toxoplasmosis combination antiparasitic drug pyrimethamine sulfadiazine , strategy evaluate prevention mother-to-child transmission . Purpose : Randomized phase 3 trial determine whether pyrimethamine + sulfadiazine effective spiramycin prevent congenital toxoplasmosis .</brief_summary>
	<brief_title>Prevention Congenital Toxoplasmosis With Pyrimethamine + Sulfadiazine Versus Spiramycine During Pregnancy</brief_title>
	<detailed_description>The protocol comparison 2 strategy prevent mother-to-child transmission T. gondii follow maternal seroconversion . Screening toxoplasmosis mandatory France . Patients confirm seroconversion eligible trial , 14 week gestational age . Participants randomly allocate one treatment group , receive open-label pyrimethamine + sulfadiazine spiramycin . The protocol change usual procedure prenatal diagnosis , change management infected fetus neonate .</detailed_description>
	<mesh_term>Toxoplasmosis</mesh_term>
	<mesh_term>Toxoplasmosis , Congenital</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Sulfadiazine</mesh_term>
	<mesh_term>Spiramycin</mesh_term>
	<criteria>&gt; 18 year old Toxoplasmosis infection acquire pregnancy document least one negative serology first trim seroconversion presence specific IgG antibody Gestational age &gt; 14 week last menstrual period Signature inform consent Lack document negative serology pregnancy Antiparasitic therapy spiramycin , pyrimethamine sulfa drug 10 day seroconversion randomization , Known allergy study drug , serious allergic condition G6PD deficiency , Known hepatic renal insufficiency , Other ongoing severe condition mother fetus Lack public health insurance</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Congenital Toxoplasmosis ,</keyword>
	<keyword>Pregnancy ,</keyword>
	<keyword>prenatal diagnosis ,</keyword>
	<keyword>mother-to-child transmission ,</keyword>
	<keyword>prevention ,</keyword>
	<keyword>spiramycine ,</keyword>
	<keyword>pyrimethamine-sulfadiazine</keyword>
</DOC>